Day 120/180 Response Cases Explained: Ultimate Guide to EMA Regulatory Lessons and Best Practices Mastering Day 120/180 Response Cases: Compliance-Ready Guide for EMA Submissions Introduction to Day 120/180 Response Cases and Their Importance Day 120/180 response cases are critical milestones in the European Medicines Agency (EMA) centralized marketing authorization review process. At these stages, the Committee for Medicinal Products for Human Use (CHMP) issues lists of questions to sponsors after initial dossier evaluations. Sponsors must provide timely and comprehensive responses to maintain review timelines and secure approvals. By 2025, Day 120 and Day 180 responses are increasingly recognized as decisive…